Ron Flauto
Company: Aurinia Pharmaceutical
Job title: Senior Medical Director - Global Medical Sciences
Seminars:
8:50 AM Chair’s Opening Remarks 8:45 am
day: Conference Day 2
3:30 PM Chair’s Closing Remarks 3:30 pm
day: Conference Day 2
4:45 PM Shifting Toward Treating Kidney Diseases Rather than Treating the Consequences of Kidney Diseases 4:45 pm
The new molecules being developed with kidney indications have shifted focus. Surrogate endpoints such as eGFR change, eGFR slope and proteinuria are innovating the treatment of kidney disease Voclosporin is a “real life” example of the use of surrogate endpoints and has changed the standard when treating lupus nephritis The impact of proteinuria reduction should…Read more
day: Conference Day 1